Tests contact radiation with short-course radiotherapy for early rectal cancer
Tests contact X-ray radiation plus short radiotherapy in adults with early rectal cancer.
Plain-language title generated from the registry record
Registry title: Contact Radiotherapy for Rectal Cancer
Key facts
- Where
- Stockholm and Uppsala, SwedenSee the 2 sites
Where in Sweden
- Karolinska University Hospital, Theme Cancer, Dept of Pelvic cancerStockholm, SwedenTaking people
- Uppsala University Hospital, Colorectal SurgeryUppsala, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alexander Valdman
- Trial code
- NCT06501053
- Record updated
- 10 August 2026
- Original description
The aim of the CORRECT phase 2 study is to show non-inferiority of Contact x-ray brachytherapy (CXB) + short-course radiotherapy (SCRT) compared to the experimental arm of the OPERA trial in organ preservation for early and early intermediate rectal cancer (cT1-3abN1).Read full original descriptionShow less
Contact Radiotherapy for Rectal Cancer (CORRECT): a Multicenter Randomized Phase II Trial
The aim of the CORRECT phase 2 study is to show non-inferiority of Contact x-ray brachytherapy (CXB) + short-course radiotherapy (SCRT) compared to the experimental arm of the OPERA trial in organ preservation for early and early intermediate rectal cancer (cT1-3abN1).
Inclusion: Adenocarcinoma of the rectum classified as:; cT1-cT3ab, < 5 cm largest diameter and < ½ circumference (MRI staging), N0-N1 (<= 3 nodes < 8mm diameter), M0; Performance status (ECOG) 0-1; Operable patient; Tumor accessible to endocavitary contact X-ray brachytherapy with a distance from the lower tumor border to the anal verge ≤10 cm; 18 years or above; No comorbidity preventing treatment; Patient having read the information note and having signed the informed consent; Follow-up possible.
Exclusion: Previous pelvic irradiation; Any significant concurrent medical illness that in the opinion of the investigator would preclude protocol therapy; Concurrent enrolment in another clinical trial using an investigational anti-cancer treatment within 28 days prior to the first dose of study treatment; Simultaneous progressive cancer; Patient with history of poor compliance or current or past psychiatric conditions or severe acute or chronic medical conditions that would interfere with the ability to comply with the study protocol; Inoperable patient; T3cd, T4, T≥ 5cm, Involvement of more than half of the bowel circumference; Distance from the lower tumor border to the anal verge >10 cm; N2-status at diagnosis or N1 with any node>= 8 mm diameter; Patient presenting with metastasis at diagnosis (M1); Tumor with extramural vascular invasion; Poorly differentiated tumor; Tumor invading external anal sphincter or growth within 1 mm of the levator; Tumor within 1 mm from MRF (mesorectal fascia); Patient unable to receive CXB or CRT; Total DPD deficiency.